IMMX

IMMX remains in a Stage 2 advancing phase with a recent momentum breakout confirming medium-term bullish bias and rising EMAs aligned beneath price. However, price is currently extended above short-term EMAs and RSI is overbought, offering no pullback into support. Therefore, while bullish execution remains valid, it is deferred until a corrective pullback into structurally supportive EMA zones.

• ↑Completed NEXICART-2 enrollment; prior 95% complete response rate heightens success odds.
• ↑Q1 GAAP EPS loss narrowed to $0.18 vs $0.212 estimate, showing efficiency gains.
• ↓Profitability metrics deeply negative, highlighting severe operational inefficiencies.